Evolus Reaches 1 Million Redemptions in its Evolus Rewards™ Patient Loyalty Program
09 June 2023 - 6:05AM
Business Wire
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a
focus on building an aesthetic portfolio of consumer brands,
announced it recently completed the one-millionth Jeuveau®
redemption through its Evolus Rewards™ patient loyalty program.
“We designed Evolus Rewards™ as the first text-based loyalty
program in the aesthetic space to create a connection with the
millennial patient population,” said David Moatazedi, President and
CEO. “In our first few years since introducing Evolus Rewards™, we
have now achieved over one million transactions and are on track to
reach all-time highs in both new and existing patients in the
second quarter. Importantly, 96% percent of patients enrolled in
Evolus Rewards™ return to their first practice for subsequent
treatments, ensuring a long-term injector-patient
relationship.”
Launched in 2020 soon after Jeuveau® was FDA approved in 2019,
Evolus Rewards™ offers enrolled patients $40 off Jeuveau®
treatments every 90 days at a participating provider’s practice. In
addition to savings every 90 days, Evolus Rewards™ also offers
patients a fun, frictionless experience delivered via text message
for ease and convenience when checking in for an appointment. With
no passwords to remember or credits to track, both patients and
practices can effortlessly participate in the program.
The Evolus Rewards™ program also delivers on the Evolus mission
of partnering with its customers to help grow their practices while
bringing in the next generation of beauty consumers considering
aesthetic injectables. On average, practices enrolled and engaged
in Evolus Rewards™ grow significantly faster than non-participating
practices.
Since launch, 600,000 patients have enrolled in Evolus Rewards™
with the majority returning for a repeat treatment. Importantly,
more than half of Evolus Rewards™ patients are millennials or
younger, a number that represents the future of the aesthetics
industry and a highly desirable demographic that providers want to
attract as they continue to grow their businesses.
About Evolus, Inc.
Evolus (Nasdaq: EOLS) is a performance beauty company evolving
the aesthetic neurotoxin market for the next generation of beauty
consumers through its unique, customer-centric business model and
innovative digital platform. Our mission is to become a global,
multi-product aesthetics company based on our flagship product,
Jeuveau® (prabotulinumtoxinA-xvfs), the first and only neurotoxin
dedicated exclusively to aesthetics and manufactured in a
state-of-the-art facility using Hi-Pure™ technology. Evolus is
expanding its product portfolio having entered into a definitive
agreement to be the exclusive U.S. distributor of Evolysse™, a line
of five unique dermal fillers currently in late-stage development.
Visit us at www.evolus.com, and follow us on LinkedIn, Twitter,
Instagram or Facebook.
Forward-Looking Statements
This press release contains forward-looking statements as
defined under the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties, including statements about
future events, our business, financial condition, results of
operations and prospects, our industry and the regulatory
environment in which we operate. Any statements contained herein
that are not statements of historical or current facts are
forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “anticipate,”
“believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,”
“potential,” “predict,” “project,” “should,” “will,” “would” or the
negative of those terms, or other comparable terms intended to
identify statements about the future. The company’s forward-looking
statements include, but are not limited to, statements related to
market conditions and consumer demand; financial and other benefits
expected from the company’s commercial outlook and its Evolus
Rewards™ program.
The forward-looking statements included herein are based on our
current expectations, assumptions, estimates and projections, which
we believe to be reasonable, and are subject to risks and
uncertainties that could cause actual results to differ materially
from those expressed or implied by the forward-looking statements.
These risks and uncertainties, all of which are difficult or
impossible to predict accurately and many of which are beyond our
control, include, but are not limited to uncertainties associated
with our ability to comply with the terms and conditions in the
Medytox Settlement Agreements, our ability to fund our future
operations or obtain financing to fund our operations, unfavorable
global economic conditions and the impact on consumer discretionary
spending, uncertainties related to customer and consumer adoption
of Jeuveau® and Evolysse™, the efficiency and operability of our
digital platform, competition and market dynamics, our ability to
successfully launch and commercialize our products in new markets,
including the Evolysse™ dermal filler product line in the U.S., our
ability to maintain regulatory approvals of Jeuveau® or obtain
regulatory approvals for new product candidates or indications, our
reliance on Symatese to achieve regulatory approval for the
Evolysse™ dermal filler product line in the U.S., and other risks
described in our filings with the Securities and Exchange
Commission, including in the section entitled “Risk Factors” in our
Annual Report on Form 10-K and our Quarterly Report on Form 10-Q
for the quarter ended March 31, 2023 expected to be filed with the
Securities and Exchange Commission on or about May 9, 2023. These
filings can be accessed online at www.sec.gov. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. Except as
required by law, we undertake no obligation to update or revise any
forward-looking statements to reflect new information, changed
circumstances or unanticipated events. If we do update or revise
one or more of these statements, investors and others should not
conclude that we will make additional updates or corrections.
Jeuveau® is a registered trademark and Evolysse™ and Evolus
Rewards™ are trademarks of Evolus, Inc. Hi-Pure™ is a trademark of
Daewoong Pharmaceutical Co, Ltd.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230608005735/en/
Investor Contact: David K. Erickson
Vice President, Investor Relations Tel: 949-966-1798 Email:
david.erickson@evolus.com
Media Contact: Email:
media@evolus.com
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Apr 2023 to Apr 2024